Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Assets (2016 - 2026)

Amphastar Pharmaceuticals has reported Assets over the past 13 years, most recently at $1.6 billion for Q4 2025.

  • For Q4 2025, Assets rose 3.29% year-over-year to $1.6 billion; the TTM value through Dec 2025 reached $1.6 billion, up 3.29%, while the annual FY2025 figure was $1.6 billion, 3.29% up from the prior year.
  • Assets for Q4 2025 was $1.6 billion at Amphastar Pharmaceuticals, down from $1.7 billion in the prior quarter.
  • Over five years, Assets peaked at $1.7 billion in Q3 2025 and troughed at $645.7 million in Q1 2021.
  • A 5-year average of $1.2 billion and a median of $1.4 billion in 2023 define the central range for Assets.
  • Biggest five-year swings in Assets: soared 112.56% in 2023 and later grew 0.04% in 2024.
  • Year by year, Assets stood at $671.5 million in 2021, then rose by 10.49% to $742.0 million in 2022, then soared by 103.9% to $1.5 billion in 2023, then grew by 4.27% to $1.6 billion in 2024, then grew by 3.29% to $1.6 billion in 2025.
  • Business Quant data shows Assets for AMPH at $1.6 billion in Q4 2025, $1.7 billion in Q3 2025, and $1.6 billion in Q2 2025.